| Autor: |
Alméciga-Diaz CJ, Hidalgo OA, Olarte-Avellaneda S; Pharmacy Department, Faculty of Science , Universidad Nacional de Colombia , Bogotá D.C. 111321 , Colombia., Rodríguez-López A, Guzman E, Garzón R, Pimentel-Vera LN, Puentes-Tellez MA, Rojas-Rodriguez AF, Gorshkov K; National Center for Advancing Translational Sciences , National Institutes of Health , Bethesda , Maryland 20892 , United States., Li R; National Center for Advancing Translational Sciences , National Institutes of Health , Bethesda , Maryland 20892 , United States., Zheng W; National Center for Advancing Translational Sciences , National Institutes of Health , Bethesda , Maryland 20892 , United States. |
| Abstrakt: |
Mucopolysaccharidosis type IVA (MPS IVA) is a rare disease caused by mutations in the gene encoding the lysosomal enzyme N -acetylgalactosamine-6-sulfate sulfatase (GALNS). We report here two GALNS pharmacological chaperones, ezetimibe and pranlukast, identified by molecular docking-based virtual screening. These compounds bound to the active cavity of GALNS and increased its thermal stability as well as the production of recombinant GALNS in bacteria, yeast, and HEK293 cells. MPS IVA fibroblasts treated with these chaperones exhibited increases in GALNS protein and enzyme activity and reduced the size of enlarged lysosomes. Abnormalities in autophagy markers p62 and LC3B-II were alleviated by ezetimibe and pranlukast. Combined treatment of recombinant GALNS with ezetimibe or pranlukast produced an additive effect. Altogether, the results demonstrate that ezetimibe and pranlukast can increase the yield of recombinant GALNS and be used as a monotherapy or combination therapy to improve the therapeutic efficacy of MPS IVA enzyme replacement therapy. |
